This Form 3 confirms OrbiMed's large pre-IPO stake and board seat, signaling strong insider alignment. Monitor for the issuer's S-1 filing and IPO pricing, which will trigger automatic conversion of preferred shares and establish a public float.
Price Chart
Executive Summary
OrbiMed Advisors and its affiliates filed a Form 3 initial statement of beneficial ownership for Electra Therapeutics, Inc. (ETRA), disclosing aggregate beneficial ownership of approximately 3.84 million shares of common stock (on an as-converted basis) held through OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. The filing is a routine initial ownership report triggered by the appointment of Carl L. Gordon to Electra's board of directors, confirming OrbiMed's significant pre-IPO stake in this clinical-stage biotech.
Key Facts
- OrbiMed Advisors LLC and affiliates filed Form 3 as initial beneficial ownership report for Electra Therapeutics, Inc.
- OrbiMed holds 2,002,310 shares of common stock (as-converted) via Series A Convertible Preferred Stock held by OrbiMed Private Investments VII, LP.
- OrbiMed holds 1,087,934 shares (as-converted) via Series B Convertible Preferred Stock held by OrbiMed Private Investments VII, LP.
- OrbiMed holds 758,279 shares (as-converted) via Series C Convertible Preferred Stock held by OrbiMed Private Investments VII, LP.
- OrbiMed holds 1,703,314 shares (as-converted) via Series C Convertible Preferred Stock held by OrbiMed Genesis Master Fund, L.P.
- Total beneficial ownership on an as-converted basis: approximately 5.55 million shares of common stock.
- Carl L. Gordon, a member of OrbiMed Advisors, has been designated to serve on Electra's board of directors.
- The Preferred Stock automatically converts into common stock 1:1 upon closing of the issuer's initial public offering.
- Each reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
Financial Impact
OrbiMed's aggregate stake represents a significant pre-IPO ownership position; no dollar value disclosed.
Risk Factors
- Pre-IPO company with no public trading history; valuation and liquidity are uncertain.
- Automatic conversion of preferred shares upon IPO will create a large public float, potentially dilutive to new investors.
- Clinical-stage biotech (SIC 2836) carries inherent pipeline and regulatory risk.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0000947871-26-000874 |
| Document: 0000947871-26-000874-index.html | 0000947871-26-000874 |
| Document: 0000947871-26-000874.txt | 0000947871-26-000874 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 28, 2026 28d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 25, 2026 4w ago | SC 13D | $11.32 $11.35 | ▲ +0.27% | ▲ +0.45% | $8.37 (−26.06%) |
Sep 23, 2026 4w ago | Insider Cluster | $11.82 $11.55 | ▼ −2.28% | ▼ −2.83% | $8.37 (−29.19%) |
Sep 21, 2026 5w ago | 3 | $13.62 $12.67 | ▼ −6.97% | ▼ −6.25% | $8.37 (−38.55%) |
Sep 18, 2026 5w ago | 424B4 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | EFFECT | $13.25 $13.92 | ▲ +5.06% | ▲ +3.51% | $8.37 (−36.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers